Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Professional Education
- Fellowship: UCLA Medical Center Obstetrics and Gynecology Fellowships (2005) CA
- Residency: UCLA Medical Center Obstetrics and Gynecology Residency (1999) CA
- Medical Education: University of Heidelberg (1989) Germany
- Board Certification: American Board of Obstetrics and Gynecology, Gynecologic Oncology (2008)
- Board Certification: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology (2006)
- PhD, University of California, Los Angeles, Molecular Biology (2003)
- Residency: Ludwig Maximillians University (1992) Germany
Honors & Awards
- American Association of Cancer Research Outstanding Poster Award, Toronto, Canada, American Association of Cancer Research, Toronto, Canada (1995)
- OB/GYN Resident Teaching Award, University of California, Los Angeles (2008)
- Outstanding Podium Presentation Award, National Gynecologic Oncology Fellow’s Forum (2004)
- STOP Cancer Career Development Award, STOP Cancer (2008)
- Teaching Award, National Council on Resident Education in Obstetrics and Gynecology (2007)
Administrative Appointments
- Director, Mary Lake Polan Gynecologic Oncology Research Laboratory (2013 - Present)
- Director, Stanford Gynecologic Oncology Clinical Care Program (2013 - Present)
- Director, Stanford Obstetrics and Gynecology, Division of Gynecologic Oncology (2013 - Present)
- Director, Stanford Clinical Research Group for Gynecologic Cancer Trials (2014 - Present)
- Director, Stanford Gynecologic Oncology Fellowship (2016 - Present)
Publications
-
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378–6385. -
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature
Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212–215. -
Specific keynote: Immunological therapy for ovarian cancer
Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105–S109. -
Gene therapy for ovarian cancer: Development of novel treatment strategies
Dorigo, O., & Berek, J. S. (1997). Gene therapy for ovarian cancer: Development of novel treatment strategies. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(1), 1–13. -
CA125: Megadaltons of novel opportunities
Dorigo, O., & Berek, J. S. (2007). CA125: Megadaltons of novel opportunities. GYNECOLOGIC ONCOLOGY, 104(3), 505–507. -
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
Karam, A., Berek, J. S., Stenson, A., Rao, J., & Dorigo, O. (2008). HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. GYNECOLOGIC ONCOLOGY, 111(3), 568–71. -
Personalizing CA125 Levels for Ovarian Cancer Screening
Dorigo, O., & Berek, J. S. (2011). Personalizing CA125 Levels for Ovarian Cancer Screening. CANCER PREVENTION RESEARCH, 4(9), 1356–1359. -
Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., & Fakhrai, H. (1998). Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. GYNECOLOGIC ONCOLOGY, 71(2), 204–210. -
Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells
Dorigo, O., Gil, J. S., Gallaher, S. D., Tan, B. T., Castro, M. G., Lowenstein, P. R., … Berk, A. J. (2004). Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. JOURNAL OF VIROLOGY, 78(12), 6556–66. -
Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.
Masghati, S., Nosratian, M., & Dorigo, O. (2014). Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy. Obstetrics and Gynecology, 123(2), 433–35. -
Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease.
Karam, A., & Dorigo, O. (2014). Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease. British Journal of Dermatology, 170(3), 661–71. -
Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm
Stoll, L. M., Parvataneni, R., Johnson, M. W., Gui, D., Dorigo, O., & Sullivan, P. (2012). Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm. HUMAN PATHOLOGY, 43(8), 1339–1343. -
Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development
Sullivan, P. S., Maresh, E. L., Seligson, D. B., Habeeb, O., Wadehra, M., Goodglick, L., & Dorigo, O. (2012). Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. MODERN PATHOLOGY, 25(8), 1140–1148. -
Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells
Fekete, M., Santiskulvong, C., Eng, C., & Dorigo, O. (2012). Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells. ANTICANCER RESEARCH, 32(2), 445–452. -
Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease
Karam, A., & Dorigo, O. (2012). Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. GYNECOLOGIC ONCOLOGY, 125(2), 346–51. -
MMPs in Ovarian Cancer as Therapeutic Targets
Karam, A., & Dorigo, O. (2012). MMPs in Ovarian Cancer as Therapeutic Targets. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 12(7), 764–72. -
Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy
Penner, K. R., Dorigo, O., Aoyama, C., Ostrzega, N., Balzer, B. L., Rao, J., … Holschneider, C. H. (2012). Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. GYNECOLOGIC ONCOLOGY, 124(3), 542–548. -
Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells
Sharma, S., Santiskulvong, C., Bentolila, L. A., Rao, J., Dorigo, O., & Gimzewski, J. K. (2012). Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 8(5), 757–766. -
Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
Dorigo, O., Santiskulvong, C., Fekete, M., Karam, A., Mulholland, D., Eng, C., & Wu, H. (2009). Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. GYNECOLOGIC ONCOLOGY, 112(2), S9–S10. -
Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression
Karam, A. K., Santiskulvong, C., Fekete, M., Zabih, S., Eng, C., & Dorigo, O. (2010). Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression. CYTOSKELETON, 67(8), 535–44. -
Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector
Gallaher, S. D., Gil, J. S., Dorigo, O., & Berk, A. J. (2009). Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector. JOURNAL OF VIROLOGY, 83(7), 3249–3257. -
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
Lipshutz, G. S., Mihara, N., Wong, R., Wallace, W. D., Allen-Auerbach, M., Dorigo, O., … Pham, P.-T. T. (2009). Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient. AMERICAN JOURNAL OF TRANSPLANTATION, 9(2), 428–432. -
Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons
Schwarz, S. C., Dorigo, O., Labarca, C., Berk, A. J., Lester, H. A., & Schwarz, J. (2004). Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons. Presented at the 8th International Congress of Parkinsons Disease and Movement Disorders, ROME,ITALY: WILEY-LISS. -
Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., Van Beveren, C., … SOBOL, R. E. (2002). Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 129(1), 99–106. -
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function
Dorigo, O., Turla, S. T., Lebedeva, S., & Gjerset, R. A. (1998). Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. JOURNAL OF NEUROSURGERY, 88(3), 535–540. -
Progress and prospects in vaccine therapy for gynecologic cancers.
Gurski, K. J., & Steller, M. A. (1997). Progress and prospects in vaccine therapy for gynecologic cancers. Oncology (Williston Park, N.Y.), 11(11), 1727-? -
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
Fakhrai, H., Shawler, D. L., VANBEVEREN, C., Lin, H., Dorigo, O., Solomon, M. J., … SOBOL, R. E. (1997). Construction and characterization of retroviral vectors for interleukin-2 gene therapy. JOURNAL OF IMMUNOTHERAPY, 20(6), 437–448. -
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., MERCOLA, D., Black, K. L., … SOBOL, R. E. (1996). Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 93(7), 2909–2914. -
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA
Shawler, D. L., Dorigo, O., Gjerset, R. A., Royston, I., SOBOL, R. E., & Fakhrai, H. (1995). COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA. JOURNAL OF IMMUNOTHERAPY, 17(4), 201–208. -
INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA
SOBOL, R. E., Fakhrai, H., Shawler, D., GJERSET, R., Dorigo, O., Carson, C., … Royston, I. (1995). INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA. GENE THERAPY, 2(2), 164–167. -
INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY
SOBOL, R. E., Royston, I., Fakhrai, H., Shawler, D. L., Carson, C., Dorigo, O., … Wilson, D. (1995). INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY. HUMAN GENE THERAPY, 6(2), 195–204. -
CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY
Gjerset, R. A., Fakhrai, H., Shawler, D. L., Turla, S., Dorigo, O., GROVERBARDWICK, A., … SOBOL, R. E. (1995). CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 31(3), 207–214. -
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS
Herndier, B., McGrath, M., Abbey, N., Wang, H. T., Ng, V., Dorigo, O., … Kohler, H. (1993). A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS. HYBRIDOMA, 12(5), 529–537. -
VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER
Dorigo, O., Meier, W., Scheidel, P., & Hepp, H. (1993). VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 254(1-4), 966–968. -
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY
ROMISCH, M., Bauer, F., Daponte, A., Meier, W., Dorigo, O., & Eiermann, W. (1993). LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 254(1-4), 1091–1093. -
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
Tillmanns, H., Neumann, F. J., Tiefenbacher, C., Dorigo, O., Parekh, N., Waas, W., … Kuebler, W. (1993). ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM. Presented at the 2nd Symposium of the German-Heart-Institute - Coronary Endothelium and Smooth Muscle : Basic Aspects and Clinical Consequences, BERLIN,GERMANY: W B SAUNDERS CO LTD. -
A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS
Muller, S., Collins, H., Brams, P., Wang, H., Dorigo, O., McGrath, M., … Kohler, H. (1993). A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS. WILEY-BLACKWELL. -
NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING
Tillmanns, H., Neumann, F. J., Waas, W., Mall, G., Parekh, N., Tiefenbacher, C., … Kubler, W. (1992). NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING. CORONARY ARTERY DISEASE, 3(7), 586–592. -
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME
Gortner, L., Pohlandt, F., Bartmann, P., Terinde, R., Versmold, H., & Dorigo, O. (1992). SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME. JOURNAL OF PERINATAL MEDICINE, 20(1), 25–28. -
PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
Tillmanns, H., Neumann, F. J., Parekh, N., Dorigo, O., Tiefenbacher, C., Zimmermann, R., … Kubler, W. (1990). PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA. EUROPEAN HEART JOURNAL, 11, 10–15. -
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
Tillmanns, H., Neumann, F. J., Parekh, N., Zimmermann, R., Tiefenbacher, C., Dorigo, O., … Kubler, W. (1990). MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 39, S9–S12. -
Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies
Muller, S., Brams, P., Collins, H., Dorigo, O., & Kohler, H. (1995). Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies. Vaccine Research, Vol 4(No 4). -
Immuno-gene therapy of colon carcinoma and central nervous tumors
Sobol, R. E., Fakhrai, H., Shawler, D. L., Dorigo, O., Gjerset, R. A., Mercola, D., … Bartholomew, R. (1996). Immuno-gene therapy of colon carcinoma and central nervous tumors. In: Gene Therapy and Cancer. -
Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma
Shawler, D. L., Dorigo, O., Van Beveren, C., Bartholomew, R. M., Fakhrai, H., & Sobol, R. E. (1997). Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma. Oncology Reports, 4(N1). -
Gene therapy for ovarian cancer – Molecular scissors of the new millenium?
Dorigo, O., & Berek, J. S. (1998). Gene therapy for ovarian cancer – Molecular scissors of the new millenium? Journal of Gynecologic Techniques, 4. -
Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., Sobol, R. E., Berek, J. S., & Fakhrai, H. (1998). Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model. Gynecologic Oncology, (71). -
Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons
Schwarz, J., Schwarz, S. C., Dorigo, O., Labarca, C., Deshpande, P., Gil, J., … Lester, H. A. (2006). Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons. The Journal of the Federation of American Societies for Experimental Biology, (20 (7). -
The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells
Sharma, S., Santiskulvong, C., Rao, J., Gimzewski, J. K., & Dorigo, O. (2014). The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. INTEGRATIVE BIOLOGY, 6(6), 611–17. -
Cervical cancer, version 2.2015.
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., … Scavone, J. L. (2015). Cervical cancer, version 2.2015. Journal of the National Comprehensive Cancer Network , 13(4), 395–404. -
Immunotherapeutic approaches to ovarian cancer treatment.
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. (2015). Immunotherapeutic approaches to ovarian cancer treatment. Journal for Immunotherapy of Cancer, 3, 7-? -
Uterine Sarcoma, Version 1.2016 Featured Updates to the NCCN Guidelines
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., … Scavone, J. L. (2015). Uterine Sarcoma, Version 1.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1321–31. -
Screening cell mechanotype by parallel microfiltration
Qi, D., Gill, N. K., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., … Rowat, A. C. (2015). Screening cell mechanotype by parallel microfiltration. SCIENTIFIC REPORTS, 5. -
Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta
Judy, A. E., Lyell, D. J., Druzin, M. L., & Dorigo, O. (2015). Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta. OBSTETRICS AND GYNECOLOGY, 126(5), 1016–18. -
Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer
Moughon, D. L., He, H., Schokrpur, S., Jiang, Z. K., Yaqoob, M., David, J., … Wu, L. (2015). Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer. CANCER RESEARCH, 75(22), 4742–52. -
Screening cell mechanotype by parallel microfiltration.
Qi, D., Kaur Gill, N., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., … Rowat, A. C. (2015). Screening cell mechanotype by parallel microfiltration. Scientific Reports, 5, 17595-? -
Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer
Minamimoto, R., Karam, A., Jamali, M., Barkhodari, A., Gambhir, S. S., Dorigo, O., & Iagaru, A. (2016). Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43(6), 1047–55. -
Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma.
Nosratian-Baskovic, M., Tan, B., Folkins, A., Chisholm, K. M., & Dorigo, O. (2016). Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma. Gynecologic Oncology Reports, 17, 38–41. -
Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., … Scavone, J. L. (2015). Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 395–404. -
Ovarian Cancer, Version 1.2016
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-may, … Hughes, M. (2016). Ovarian Cancer, Version 1.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(9), 1134–63. -
Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons
Schwarz, J., Schwarz, S. C., Dorigo, O., Stuetzer, A., Wegner, F., Labarca, C., … Lester, H. A. (2006). Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons. FASEB JOURNAL, 20(7), 935–946. -
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K.-Y. M., Karam, A., Mulholland, D., … Dorigo, O. (2011). Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma. CLINICAL CANCER RESEARCH, 17(8), 2373–2384. -
Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma
Shawler, D. L., Dorigo, O., VANBEVEREN, C., Bartholomew, R. M., Fakhrai, H., & SOBOL, R. E. (1997). Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma. ONCOLOGY REPORTS, 4(1), 135–138. -
Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.
He, H., Chiu, A. C., Kanada, M., Schaar, B. T., Krishnan, V., Contag, C. H., & Dorigo, O. (2017). Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer. Molecular Imaging and Biology . -
Immunotherapy in ovarian cancer.
Krishnan, V., Berek, J. S., & Dorigo, O. (2016). Immunotherapy in ovarian cancer. Current Problems in Cancer. -
Vulvar Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
Koh, W.-J., Greer, B. E., Abu-Rustum, N. R., Campos, S. M., Cho, K. R., Chon, H. S., … Scavone, J. (2017). Vulvar Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(1), 92–120. -
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-may, … Hughes, M. (2016). Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 14(9), 1134–1163. -
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2017). Immunotherapy in ovarian cancer. CURRENT PROBLEMS IN CANCER, 41(1), 48–63. -
Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682. -
Tumor associated macrophages in gynecologic cancers.
Krishnan, V., Schaar, B., Tallapragada, S., & Dorigo, O. (2018). Tumor associated macrophages in gynecologic cancers. Gynecologic Oncology. -
Cell-based immunotherapy in gynecologic malignancies.
Schaar, B., Krishnan, V., Tallapragada, S., & Dorigo, O. (2018). Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology, 30(1), 23–30. -
Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., … Scavone, J. L. (2018). Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(2), 170–99. -
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials
MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A., … Kohn, E. C. (2017). Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. ONCOTARGET, 8(48), 84579–94. -
Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis.
Foreman, K., Fuh, K., SorianoJAL, M., Dorigo, O., Krishnan, V., Shehade, H., … Rankin, E. (2018). Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis. CLINICAL CANCER RESEARCH, 24(15), 57. -
Women's cancer: Advancing molecular and immunotherapy
Dorigo, O. (2017). Women's cancer: Advancing molecular and immunotherapy. CURRENT PROBLEMS IN CANCER, 41(1), 7. -
Single cell analysis of ascites macrophages in ovarian cancer
He, H. M., Yu, F. B., Quake, S. R., & Dorigo, O. (2015). Single cell analysis of ascites macrophages in ovarian cancer. CANCER RESEARCH, 75. -
Parallel microfiltration (PMF): A novel method to screen cell mechanotype
Wiedemeyer, W.-R., Qi, D., Gi, N. K., Santiskulvong, C., Dorigo, O., Rao, J. Y., … Rowat, A. C. (2015). Parallel microfiltration (PMF): A novel method to screen cell mechanotype. CANCER RESEARCH, 75. -
Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options.
Elvin, J. A., Bailey, M., Carneiro, B. A., Ali, S. M., Vergilio, J.-A., Palma, N. A., … Dorigo, O. (2015). Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer
Moughon, D., He, H., Schokrpur, S., Jiang, Z., Yaqoob, M., David, J., … Wu, L. (2015). M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer. CANCER RESEARCH, 75(1). -
Mutational analysis of serous ovarian cancer using Ion Torrent sequencing
Masghati, S., Dorigo, O., & Santisvkulvong, C. (2014). Mutational analysis of serous ovarian cancer using Ion Torrent sequencing. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
The role of tumor associated macrophages in ovarian cancer
He, H., Moughon, D. L., Hillerup, C., ElMasri, W., Wu, L., & Dorigo, O. (2014). The role of tumor associated macrophages in ovarian cancer. GYNECOLOGIC ONCOLOGY, 135(2), 385. -
Cell-based immunotherapy in gynecologic malignancies.
Schaar, B., Krishnan, V., Tallapragada, S., Chanana, A., & Dorigo, O. (2018). Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. -
A scalable filtration method for high throughput screening based on cell deformability.
Gill, N. K., Ly, C., Nyberg, K. D., Lee, L., Qi, D., Tofig, B., … Rowat, A. C. (2018). A scalable filtration method for high throughput screening based on cell deformability. Lab on a Chip. -
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., … Scavone, J. L. (2019). Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 17(1), 64–84. -
Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., … Rankin, E. B. (2019). Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Research. -
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins.
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., … Bertozzi, C. R. (2019). The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proceedings of the National Academy of Sciences of the United States of America. -
Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States.
Renz, M., Diver, E., English, D., Kidd, E., Dorigo, O., & Karam, A. (2019). Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States. Journal of Minimally Invasive Gynecology. -
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., … Bertozzi, C. R. (2019). The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 116(15), 7278–87. -
Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis
Natarajan, S., Foreman, K. M., Soriano, M., Rossen, N. S., Shehade, H., Fregoso, D. R., … Rankin, E. B. (2019). Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis. CANCER RESEARCH, 79(9), 2271–84. -
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx.
Möckl, L., Pedram, K., Roy, A. R., Krishnan, V., Gustavsson, A.-K. K., Dorigo, O., … Moerner, W. E. (2019). Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx. Developmental Cell. -
Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.
Levinson, K., Dorigo, O., Rubin, K., & Moore, K. (2019). Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (39), e126–e140. -
Omentum immune microenvironment: Metastatic niche for ovarian cancer
Krishnan, V., Raju, P. A., Vierkoetter, K., Patel, S., Youngyunpipatkul, J., Tallapragada, S., … Dorigo, O. (2018). Omentum immune microenvironment: Metastatic niche for ovarian cancer. CANCER RESEARCH, 78(13). -
ASCO 2019 meeting review.
Diver, E., Dorigo, O., & Berek, J. (2019). ASCO 2019 meeting review. Journal of Gynecologic Oncology, 30(5), e107. -
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., … Weissman, I. L. (2019). CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. -
DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression.
Tanyi, J. L., Dorigo, O., Oza, A. M., Strauss, J. F., Pejovic, T., Ghamande, S. A., … Rosu, G. N. (2019). DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
C-C chemokine receptor type 1 is a prognostic indicator in ovarian cancer
Chanana, A. M., Krishnan, V., Tallapragada, S., & Dorigo, O. (2019). C-C chemokine receptor type 1 is a prognostic indicator in ovarian cancer. CANCER RESEARCH, 79(13). -
THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING
Natarajan, S., Foreman, K., Soriano, M., Shehade, H., Fregoso, D., Eggold, J., … Rankin, E. B. (2019). THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING. CLINICAL CANCER RESEARCH, 25(22), 168. -
OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS
Krishnan, V., Tallapragada, S., Schaar, B., Chanana, A., Rinker-Schaeffer, C., & Dorigo, O. (2019). OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS. CLINICAL CANCER RESEARCH, 25(22), 162. -
Gestational Trophoblastic Neoplasia, Version 2.2019
Abu-Rustum, N. R., Yashar, C. M., Bean, S., Bradley, K., Campos, S. M., Chon, H. S., … Scavone, J. (2019). Gestational Trophoblastic Neoplasia, Version 2.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(11), 1374–91. -
Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States
Renz, M., Diver, E., English, D., Kidd, E., Dorigo, O., & Karam, A. (2020). Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 27(2), 482–88. -
Quantitative super-resolution microscopy of the mammalian glycocalyx
Mockl, L., Pedram, K., Roy, A., Krishnan, V., Gustavsson, A.-K., Dorigo, O., … Moerner, W. (2019). Quantitative super-resolution microscopy of the mammalian glycocalyx. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC. -
DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer
Dorigo, O., Fiset, S., MacDonald, L. D., Bramhecha, Y., Hrytsenko, O., Dirk, B., … Stanford, M. (2020). DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(5). -
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito, I., Bellati, F., Ray-Coquard, I., Mirza, M. R., du Bois, A., Gasparri, M. L., … Braicu, E. I. (2020). Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews, 87, 102040. -
Minimally Invasive Surgery for Gynecologic Cancers-A Cautionary Tale.
Karam, A., & Dorigo, O. (2020). Minimally Invasive Surgery for Gynecologic Cancers-A Cautionary Tale. JAMA Oncology. -
Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review.
Johnson, S., Renz, M., Wheeler, L., Diver, E., Dorigo, O., Litkouhi, B., … Karam, A. (2020). Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. -
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.
Shon, D. J., Malaker, S. A., Pedram, K., Yang, E., Krishnan, V., Dorigo, O., & Bertozzi, C. R. (2020). An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins. Proceedings of the National Academy of Sciences of the United States of America. -
Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1.
Krishnan, V., Tallapragada, S., Schaar, B., Kamat, K., Chanana, A. M., Zhang, Y., … Dorigo, O. (2020). Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Communications Biology, 3(1), 524. -
Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa).
Dorigo, O., MacDonald, L. D., Schindler, J., Bramhecha, Y., Torrey, H., Kaliaperumal, V., … Fiset, S. (2020). Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Development of Therapeutic Vaccines for Ovarian Cancer.
Chow, S., Berek, J. S., & Dorigo, O. (2020). Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines, 8(4). -
Cell-based immunotherapy in gynecologic malignancies.
Kamat, K., Krishnan, V., Berek, J. S., & Dorigo, O. (2020). Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. -
Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice.
Levy, K., Natarajan, S., Wang, J., Chow, S., Eggold, J. T., Loo, P. E., … Rankin, E. B. (2020). Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice. Scientific Reports, 10(1), 21600. -
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
Shon, D. J., Malaker, S. A., Pedram, K., Yang, E., Krishnan, V., Dorigo, O., & Bertozzi, C. R. (2020). An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins. GLYCOBIOLOGY. OXFORD UNIV PRESS INC. -
Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
Rahimy, E., Usoz, M., von Eyben, R., Fujimoto, D., Watanabe, D., Karam, A., … Kidd, E. (2021). Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors. Gynecologic Oncology. -
FLASH irradiation enhances the therapeutic index of abdominal radiotherapy in mice
Natarajan, S., Levy, K., Wang, J., Chow, S., Eggold, J., Loo, P., … Rankin, E. B. (2020). FLASH irradiation enhances the therapeutic index of abdominal radiotherapy in mice. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Total abdominal ultra-rapid FLASH irradiation enhances the efficacy of PD-1 inhibition in preclinical models of ovarian cancer
Chow, S., Eggold, J. T., Levy, K., Wang, J., Manjappa, R., Breitkreutz, D. Y., … Rankin, E. B. (2020). Total abdominal ultra-rapid FLASH irradiation enhances the efficacy of PD-1 inhibition in preclinical models of ovarian cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Kassuhn, W., Klein, O., Darb-Esfahani, S., Lammert, H., Handzik, S., Taube, E. T., … Braicu, E. I. (2021). Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. Cancers, 13(7). -
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I., Oaknin, A., … McNeish, I. A. (2021). Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 12(1), 2487. -
Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary.
Moon, A. S., & Dorigo, O. (2021). Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary. Gynecologic Oncology Reports, 36, 100770. -
Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
Qian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., … Rankin, E. B. (2021). Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. The Journal of Clinical Investigation, 131(16). -
Phase II Trial Evaluating Efficacy of a Fitbit Program for Improving the Health of Endometrial Cancer Survivors
Rahimy, E., Usoz, M., von Eyben, R., Fujimoto, D., Watanabe, D., Karam, A., … Kidd, E. (2021). Phase II Trial Evaluating Efficacy of a Fitbit Program for Improving the Health of Endometrial Cancer Survivors. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.
Devereaux, K. A., Weiel, J. J., Pors, J., Steiner, D. F., Ho, C., Charu, V., … Howitt, B. E. (2021). Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. -
Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.
Kassuhn, W. N., Klein, O., Darb-Esfahani, S., Lammert, H., Handzik, S., Taube, E. T., … Braicu, E. I. (2021). Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.
Eggold, J. T., Chow, S., Melemenidis, S., Wang, J., Natarajan, S., Loo, P. E., … Rankin, E. B. (2021). Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer. Molecular Cancer Therapeutics. -
Cell-based immunotherapies in gynecologic cancers.
Lang, S. M., & Dorigo, O. (1800). Cell-based immunotherapies in gynecologic cancers. Current Opinion in Obstetrics & Gynecology, 34(1), 10–14. -
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
Kibbi, N., Owen, J. L., Worley, B., Wang, J. X., Harikumar, V., Downing, M. B., … Alam, M. (2022). Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology. -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., … Gourley, C. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet (London, England), 399(10324), 541–553. -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., … Gourley, C. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. LANCET, 399(10324), 541–553. -
IDENTIFICATION OF POTENTIAL RESPONSE PREDICTORS TO MAVEROPEPIMUT-S (DPX-SURVIVAC), A NOVEL T CELL ACTIVATING IMMUNOTHERAPY, IN PATIENTS WITH ADVANCED RECURRENT OVARIAN CANCER
Dorigo, O., Ebrahimizadeh, W., Kennedy, B., MacDonald, L., Fiset, S., Villella, J., … Bramhecha, Y. (2021). IDENTIFICATION OF POTENTIAL RESPONSE PREDICTORS TO MAVEROPEPIMUT-S (DPX-SURVIVAC), A NOVEL T CELL ACTIVATING IMMUNOTHERAPY, IN PATIENTS WITH ADVANCED RECURRENT OVARIAN CANCER. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke, C., Kulbe, H., Dreher, F., Taube, E. T., Chekerov, R., Horst, D., … Braicu, E. I. (2022). Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. Gynecologic Oncology. -
Revealing the human mucinome.
Malaker, S. A., Riley, N. M., Shon, D. J., Pedram, K., Krishnan, V., Dorigo, O., & Bertozzi, C. R. (2022). Revealing the human mucinome. Nature Communications, 13(1), 3542. -
Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
Kamat, K., Krishnan, V., & Dorigo, O. (2022). Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer. British Journal of Cancer. -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., … Gourley, C. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. LANCET, 399(10324), 541–553. -
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote, I., Gonzalez-Martin, A., Lorusso, D., Gourley, C., Mirza, M. R., Kurtz, J.-E., … Bookman, M. A. (2022). Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. The Lancet. Oncology, 23(8), e374–e384. -
Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.
Reddy, R. A., Moon, A. S., Chow, S., Heilbroner, L., Howitt, B., Diver, E., … Karam, A. (2022). Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer. Gynecologic Oncology Reports, 43, 101054. -
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS)Consortium.
Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., … Braicu, E. I. (2022). Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS)Consortium. Annals of Surgical Oncology. -
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., … Braicu, E. I. (2022). ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Annals of Surgical Oncology. -
Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy.
Chow, S., & Dorigo, O. (2022). Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer »
- CT Antigen TCR-redirected T Cells for Ovarian Cancer »
- Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer »
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients »
- Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) »
- Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN »
- A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer »
- Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer »
Practice Locations
Gynecologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Gynecologic Cancer Program in Palo Alto
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CA
Stanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(148 reviews)
Dr. Dorigo was incredibly knowledgeable and compassionate. I feel extremely grateful to have such good care.
Knowledgeable, accomplished, excellent provider. Provides thorough responses and analysis. Listens and allows for patient questions and input.
Very Nice
He listened to my concerns and reviewed notes from another doctor I am seeing that referenced a possible solution to the medical condition they are treating me for. I thank him for that.
Dr Dorigo had a very detailed explanation about my condition now. He is terrific !
Dr. Dorigo is outstanding. Expert care, empathic and educates the patient.
Very happy with Dr Dorigo’s care. I feel he has my best interest in my care. I feel fortunate to have him as my care provider.
Personable, thorough, did not rush, answered questions well.
He is very professional and Knowledgeable with Nice Heart and Kindness Attitude. There is no words can Express my GRATEFULNESS.
God bless him .
Dr Dorigo is so personable, professional, and reassuring. I feel so fortunate to have found him for my treatment. His assistant, Becky, and his staff are all attentive, professional, and all around great!
Dr. Dorigo and staff are empathic, informative and factual.
Dr Dorigo is spectacular. Incredibly knowledgeable, kind, and empathetic.
Team is great love them
Best Dr. in the world!
Dr Dorigo is awesome. He’s an excellent doctor. And very caring and patient. Did not rush through the appointment.
Explains thoroughly, answers questions, shows images and results.
He is the very best…..especially since he saved my life!
Dr Dorigo was extremely informative and thorough., eager to answer questions, and arrange for follow-up.. Staff very professional.
Dr. Dorigo and staff are outstanding.
Dr. Dorigo is extremely caring, kind, patient, compassionate, knowledgeable and professional. He and his team make me feel that I am in good hands. They seem to be on top of everything and I truly appreciate the professionalism.
Dr. Dorigo is an exceptional care provider
Dr. Dorigo stands out in how he answers questions completely and provided me more detailed information and assurances that I’ve ever had from a physician during a difficult time. If he is your doctor, you won’t be disappointed. Knowledgeable and thorough. The best!
We love Dr Dorigo and the efficiency of Stanford
He was very friendly and professional. He and Ashley Wood answered all my questions.
excellent doctor, not rushed & explained things well
He is superb. I have already recommended him to two fellow ovarian cancer friends.
He is an excellent surgeon & oncologist.I trust him explicitly.
Dr. Dorigo is the very best.
Lucky to have you in charge of my care
Dr. Dorigo and all the staffs are wonderful! They really care about their patients and support me in every way they can. I really appreciate them!
I appreciate the care and concern shown to me by Dr. Dorigo! His team was present and so helpful in obtaining recent diagnostics done outside of Stanford that helped guide the treatment plan for me.
Excellent
Absolutely. Dr. Dorigo is excellent!
I believe he is a wonderful, caring Doctor & surgeon & has a great staff.
I am so blessed that I have been referred to
Dr Oliver Dorigo. Though today was only the 1st meeting which I had with him, however, I could already feel his precision in his
recommendations and judgements.
A cancer patient like me needs
a doctor like him who can give me accurate direction for my cancer journey.
It is obvious that he is working very hard and has brought inother to help make a plan for treatment
Yes…he is a Saint.
Doctor Doritos is a caring and excellent doctor. I drive 4 hours to have him as my doctor/surgeon.
He listened and was honest about what he could answer and what he couldn't. Made time for my questions and was patient.
He is a very knowledgable and compassionate doctor. I trust his opinion very much and highly recommend him.
Dr. Dorigo and his team are the best. I can't be happier with the care I received from him and his team. Thank you again!
I like Dr. Dorigo and appreciate his knowledge and professional excellence on my behalf. My scheduled appt. was about 45 minutes late, with me being unsure I’d done everything right to connect, so that was unsettling, but
I’m sure that was out of his control. It would have been easier for me if he had removed the face mask so I could better understand him. And then knowing his part regarding the needed referral could be better understood so I can know how I proceed.
He is an excellent doctor
Thank you for making my journey so comfortable, I did feel like i was important and that you care.
I can’t remember ever meeting a nicer doctor. Very professional, yet very warm. I feel very blessed to have such a knowledgeable doctor in charge of my care.
Dr Dorigo is a truly exceptional clinician. He listens, he considers options, he’s highly knowledgeable and he’s encouraging. He always makes me feel like I matter and that my stage IV ovarian cancer is being treated appropriately and with consideration for my quality of life. I appreciate him immensely.
Dr. Dorigo and the staffs are amazing! Thank you!
Dr. Dorigo has been supported me since day one until present. He understands the seriousness of my disease. He explained treatments to me that I understood very clear. He gives detailed informations of options about my treatments. I would like Dr. Dorigo to continue helped in my treatments.
He’s a very good Oncologist that I want to keep treating me. Thank you
Dr. Dorigo is a wonderful doctor. He very helpful, experienced, kind, explained my condition very well, answered my questions, gave me options, etc. I’m very grateful for his help.
Very thorough and articulate. I felt heard and valued in the process
Amazing Doctor!
Knows how to connect and build relationships.
Good listener.
Dr Dorigo is very warm, extremely well prepared and helpful about any questions about any aspect of my medical care — meaning he treats the entire person not just a body part
He’s accessible and completely transparent respecting his patient’s intelligence and time
Extremely easy to talk to, thorough, reassuring.
Dr. Dorigo was very kind and clear. I felt he really listened to me and his explanations were easy to follow.
Outstanding individual. Grateful that he is my surgeon.
I trust him and know he has my best interest at heart and will take care of me.
Sent a letter to David Entwistle conveying my sincere gratitude for the care received from Dr. Oliver Dorigo and his staff.
Dr. Dorigo & his staff (especially Becky) are amazing.
Dr. Dorigo was informative positive and knowledgeable. I enjoyed his enthusiasm about the outcome of my surgery.
Dr. Dorigo spent plenty of time explaining and describing where we were in treatment. He listened to me and addressed all questions. He is the best doctor and I am thrilled he is handling my care.
Follow ups to cancer surgery & chemo - excellent, caring but still professional care. 5 star in all ways!!
The care provider advisor explained possible after side effects after the surgery and explained what could and advised me who and what to do afterward. He also told me how to take care of area around incision.
Excellent, detailed.
Excellent care.
Dr. Dorigo is amazing. He is incredibly knowledgeable, he explains everything very clearly. I feel I have the best care possible. He is kind, compassionate & has a good sense of humor.
I have trusted Dr. Dorigo with my life I came in very, very sick and he has help me a lot.
It was important that I get in to see Dr. Dorigo to discuss some current issues with my health. He was able to see me on short notice and spent a good deal of time having a discussion with me regarding the clinical trial I am currently on and a plan moving forward. He was very thorough in explaining everything to me.
Dr. Dorigo is highly recommended!
Dr. Dorigo is absolutely awesome! He was very thorough in explaining everything. Answered most of my questions before I even asked them, then patiently answered the rest.
Dr. Dorigo is an excellent physician with an extensive clinical & research interest in the rare cancer I've had. I self referred myself after extensive research to find and expert in the field & was glad I did so.
I like Dr. Dorigo very much.
Dr. Dorigo was superb! I will be switching my care over to him and Stanford after July!
Very good experience w/Dr. Dorigo. Like his bedside manner, does help translate in more understandable words. Most of the ONC Gync. is very complicated, and he was great!
I like & trust Dr. Dorigo.
Dr. Dorigo is thoroughly brilliant, focused on my condition, asks questions & listens.
Amazing! Dr. Dorigo is SO caring & extremely bright and dedicated. His calm, confident demeanor always put me at ease.
Dr. Dorigo & the assistant (who collected my info & Q's before doctor came in) were both courteous & thorough answering my Q's. I was there for a 2nd opinion & left confident that I had info I needed to decide on treatment course.
Dr. Dorigo was very thorough a very accommodating. He wasn't rush & was very receptive & encouraging. He was excellent. Dr. Torino - was very good as well.
A wonderful doctor, very happy with him!
Dr. Dorigo is an excellent surgeon & physician.
Expected 10 minutes so 20 minutes exceeded expectations. He was kind to show me my CT images. Dr. Dorigo speaks fast with an accent, is sometimes hard to understand.
I have had bad experiences with doctors & hospital staff before. However, I don't have 1 bad thing to say about Stanford.
Exceptional in every way!
This was one of the best dr. experiences I have ever had in a really terrible situation. He gave me hope again.
Good.
Very professional doctor, nurse practitioner, and nurse.
Excellent explanation of problem & care of it.
The doctor made me feel relaxed and not as stressed.
I couldn't ask for a better or more skilled doctor!
I have full confidence that Dr. Dorigo is exceptionally knowledge re: My condition while conducting the appointment in a very caring, attentive manner.
I have been a cancer patient under the care of Dr. Dorigo for four years and have received excellent care.
Dr. Dorigo was excellent - he explained things thoroughly & patiently; took time answering my questions & respond to my concerns; and he had an all-around friendly & confidence-instilling manner.
I feel blessed because God put on my path a doctor like Dr. Dorigo. Finally someone answered my questions. Dr. Dorigo is such an amazing doctor may he be blessed with many years of practicing medicine. This world needs doctors like him.
Dr. Dorigo was very nice and informative.
Has a hard time staying focused! Never pertinent information to issue.
Dr. Dorigo was incredible! He's very knowledgeable, very good at explaining things he spent plenty of time with me and listened carefully to my question.
Dr. Oliver Dorigo is the most wonderful doctor in this world. He saved MY LIFE!! Thank you Dr. Dorigo.
This was a referral consultation for a second opinion. Dr. Dorigo was familiar with my file from Kaiser and was prepared with a number of suggestions and next steps. The team was respectful and helpful.
Dr. Dorigo and Arthie (NP) were both very cordial spent sufficient time with me, and answered my questions.
This care team is highly knowledgeable and responsive. I was extremely impressed. Received answers to health questions my internist in Monterey did not accurately answer.
Dr. Dorigo spent ample time with me, & answered all questions & concerns.
I feel blessed & be under Dr. Dorigo's care.
Dr. Dorigo's (his) MA & NP were present during the appointment to take notes and collaborate.
Dr. Dorigo - excellent!
I am sure he is a qualified dr. but for me - he has no bedside manner. He seeing rushed, always in a hurry. Not a favorite of mine.
Dr. Dorigo did an excellent job of explaining my options. I will be getting chemo @ St. Mary's in SF, but overall treatment will be directed by Dr. Dorigo.
Excellent service.
If I have waited some time, I should understand, that my specialist doctor can be very busy attending an urgency & serious delicacy of a patient.
Dr. Dorigo has a wonderful manner about him. He also explained everything in details we fully understood. Answered all our questions. Everyone was very helpful.
He is rushed. No bedside manner. I drive 35 miles one way to go to Stanford. He spends about one minute with me. Sometime I think it is a waste of time.
I highly recommend Dr. Dorigo. He is highly skilled, compassionate & caring.
My specialist Dr. Dorigo is eminent, respectful, friendly, comprehensive and courteous.
The doctor was very gentle-thanks!
I saw Dr. Dorigo for a 2nd opinion. Very compassionate; explained to well & answered all my questions. I would highly recommend this gynecologist.
Excellence service.
Women's Cancer Center, and Dr. Dorigo's entire team, are doing a commendable job.
The fellow Dr. Swanson & Dr. Dorigo make a good team. Dr. Swanson spent a lot of time with me & had a lot of good explanations about things. Dr. Dorigo is short & to the point & also had helpful input.
Dr. Dorigo and his resident were very kind. I appreciate the gentleness with which he performed my pelvic exam and his willingness to discuss.
He is by far the best doc I have ever seen. Brilliant, humble, kind, loving & compassionate.
The staff is fast in answering a question and with good treatment.
Dr. Dorigo was GREAT! His front office staff are a poor reflection on how amazing him and his nursing staff are.
Dr. Dorigo is the best!
Great.
I have full confidence in Dr. Dorigo.
To me the doctor attended me well despite that he would explain in Spanish.
Have total confidence in Dr. Dorigo.
May God bless the hospital of Stanford & all its personnel, for the good humanity.
Dr. Dorigo explained things well & didn't make us feel rushed. He instilled much confidence.
Very interested doctor in my health and so that my treatment be efficient.
From a pt.'s perspective Dr. Dorigo is one of the most outstanding physicians I've been treated by (and I'm a nurse). I was afraid I was going to be given a devastating diagnosis, and he was not only clinically stellar, but kindly and professionally demonstrated that he understood the stress I was feeling, and really moved the treatment along quickly! I was most grateful!!!
Very happy with Dr. Dorigo. He seems like he really cares about you as a person.
Good.
Dr. Dorigo is excellent. Very happy to be his patient.
This was a second opinion, the entire staff was very helpful and considerate. I was VERY pleased with the visit.
Everything was perfect.
Lab results where not given to me until I e-mailed thru "Myhealth". So my concern level was heightened.
Dr. Dorigo is the most caring and intelligent doctor I have ever had! Thank you Dr. Dorigo.
Dr. Dorigo is an amazing doctor, very caring, knowledgeable and friendly!
Follow through post appt. has been disappointing. No one has done what they said other than order tests but leaving coordination to me when told otherwise.
Dr. Dorigo is an excellent doctor. I like the way he treats me as a patient.
I love him.
I liked that both Dr. Dorigo and his nurse called the next day after surgery to check on my well-being.
Dr. Dorigo is the most caring and intelligent doctor I encountered throughout my cancer journey. He is the biggest blessing to me throughout this journey!
Dr. Oliver Dorigo went above and beyond with patience and understanding with me as I completely emotionally, fell apart after my diagnosis. He took more time than he should have.
Good experience.
I did my "homework" on Dr. Dorigo before my appointment and was impressed but once I met him - I knew I was in excellent "hands".
He is always attentive and willing to listen & help.
Utmost respect for Dr. Dorigo! Knowledgeable, caring, shows concern, genuine & thorough.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
- Send referrals online
- View referral status
- Access medical records